About Zolbetuximab
            
            Class: | Monoclonal antibody (anti-CLDN18.2)  
Use: | Treatment of adults with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing CLDN18.2, in combination with chemotherapy  
Adult dose: | 100 mg/m² administered as an intravenous infusion every 2 weeks, in combination with chemotherapy  
Pediatric dose: | Safety and efficacy have not been established in pediatric patients  
Side effects: | Nausea, vomiting, diarrhea, fatigue, infusion-related reac
         
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.